glp-1 usage by state North America Glucagon-Like Peptide-1 (GLP-1) Agonist Market Products - Data Briefs -

Shotsy includes customizable side effect logs so you can record issues like nausea, headaches, and fatigue

[18] [5] Rapid weight loss associated with this class of medication may increase the risk of gallbladder disease, including gallstones

This reduces early discomfort

Some are approved for type 2 diabetes, while others are approved for chronic weight management in patients with a qualifying BMI

The agency also emphasised that the medication alone would not reverse the trend in obesity, which it recognised as a complex, chronic disease and a major driver of non-communicable diseases, including cardiovascular disease, type-2 diabetes and some types of cancer

p = 0.0001) (287)